Table 3.
CD | UC | Control | ORCD | 95% CI1 | P value | ORUC | 95% CI1 | P value | |
NF-κB -94ins/del | |||||||||
II | 107 | 175 | 267 | 1.00 | - | 1.00 | - | ||
ID | 165 | 233 | 385 | 1.08 | 0.80-1.46 | 0.62 | 0.94 | 0.72-1.21 | 0.62 |
DD | 55 | 87 | 127 | 1.21 | 0.81-1.81 | 0.36 | 1.04 | 0.73-1.47 | 0.83 |
ID and DD | 220 | 320 | 512 | 1.11 | 0.83-1.48 | 0.48 | 0.96 | 0.75-1.23 | 0.76 |
PPARγ Pro12Ala | |||||||||
CC | 240 | 364 | 549 | 1.00 | - | 1.00 | - | ||
CG | 84 | 116 | 217 | 0.88 | 0.65-1.20 | 0.43 | 0.83 | 0.63-1.09 | 0.17 |
GG | 3 | 15 | 13 | 0.48 | 0.13-1.77 | 0.27 | 2.30 | 1.04-5.08 | 0.04 |
CG and GG | 87 | 131 | 230 | 0.86 | 0.64-1.16 | 0.33 | 0.90 | 0.69-1.17 | 0.42 |
PPARγ C1431T | |||||||||
CC | 241 | 352 | 561 | 1.00 | - | 1.00 | - | ||
CT | 78 | 128 | 205 | 0.81 | 0.59-1.12 | 0.20 | 1.00 | 0.76-1.31 | 0.99 |
TT | 8 | 15 | 13 | 1.36 | 0.54-3.42 | 0.52 | 1.95 | 0.90-4.27 | 0.09 |
CT and TT | 86 | 143 | 218 | 0.85 | 0.62-1.15 | 0.29 | 1.05 | 0.81-1.37 | 0.69 |
PXR rs1523127 | |||||||||
AA | 114 | 160 | 280 | 1.00 | - | 1.00 | - | ||
AC | 167 | 250 | 366 | 1.06 | 0.79-1.43 | 0.71 | 1.15 | 0.89-1.50 | 0.29 |
CC | 46 | 85 | 133 | 0.89 | 0.59-1.35 | 0.59 | 1.11 | 0.78-1.56 | 0.57 |
AC and CC | 213 | 335 | 499 | 1.02 | 0.77-1.35 | 0.91 | 1.14 | 0.89-1.46 | 0.30 |
PXR rs2276707 | |||||||||
CC | 223 | 339 | 517 | 1.00 | - | 1.00 | - | ||
CT | 94 | 147 | 241 | 0.92 | 0.68-1.24 | 0.57 | 0.97 | 0.75-1.26 | 0.84 |
TT | 10 | 9 | 21 | 1.25 | 0.56-2.76 | 0.58 | 0.67 | 0.30-1.51 | 0.33 |
CT and TT | 104 | 156 | 262 | 0.94 | 0.71-1.26 | 0.69 | 0.95 | 0.74-1.22 | 0.68 |
PXR rs6785049 | |||||||||
AA | 137 | 184 | 334 | 1.00 | - | 1.00 | - | ||
AG | 152 | 247 | 343 | 1.12 | 0.84-1.49 | 0.46 | 1.35 | 1.05-1.74 | 0.02 |
GG | 38 | 64 | 102 | 0.91 | 0.58-1.40 | 0.66 | 1.18 | 0.81-1.71 | 0.39 |
AG and GG | 190 | 311 | 445 | 1.07 | 0.81-1.40 | 0.65 | 1.31 | 1.03-1.66 | 0.03 |
LXR rs1405655 | |||||||||
TT | 143 | 229 | 383 | 1.00 | - | 1.00 | - | ||
CT | 149 | 217 | 313 | 1.26 | 0.95-1.68 | 0.11 | 1.22 | 0.95-1.57 | 0.11 |
CC | 35 | 49 | 83 | 1.12 | 0.71-1.78 | 0.62 | 1.01 | 0.67-1.51 | 0.97 |
CT and CC | 184 | 266 | 396 | 1.23 | 0.94-1.62 | 0.13 | 1.18 | 0.93-1.49 | 0.17 |
LXR rs2695121 | |||||||||
TT | 62 | 88 | 170 | 1.00 | - | 1.00 | - | ||
CT | 168 | 254 | 387 | 1.28 | 0.90-1.83 | 0.17 | 1.30 | 0.95-1.77 | 0.10 |
CC | 97 | 153 | 222 | 1.21 | 0.82-1.79 | 0.34 | 1.41 | 1.00-1.98 | 0.05 |
CT and CC | 265 | 407 | 609 | 1.26 | 0.89-1.76 | 0.19 | 1.34 | 0.99-1.79 | 0.06 |
Statistical analyses included subjects for whom all information was available.
Adjusted for age, sex and smoking status. NF-κB: Nuclear factor κB; PPARγ: Peroxisome proliferator-activated receptor γ; CD: Crohn’s disease; UC: Ulcerative colitis; OR: Odds ratio; PXR: Pregnane X receptor; LXR: Liver X receptor.